linjc16/ctgov huggingface dataset:
Inflammatory Markers for Postoperative Complications in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Study Overview
=================
Brief Summary
-----------------
Infective complications after cancer surgery had a significant impact on disease-free and overall survival. Postoperative inflammatory markers have been proven useful in predicting infective complications. However, it remains unknown whether these markers can predict postoperative infection in patients receiving cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) which causes the systemic inflammatory response syndrome. Between September 2014 and April 2017, all patients who underwent cytoreductive surgery and HIPEC for peritoneal carcinomatosis were assessed for postoperative complications. Patients were divided into two groups according to the presence of infective complications. Presence of abscess, positive blood, surgical site, urine or sputum cultures, or clinical signs and symptoms with comparable radiologic findings were defined as infective complications. Retrospectively, C-reactive protein (CRP), neutrophil-to-lymphocyte ratio, white blood cell count, platelet count, mean platelet volume, platelet-to-lymphocyte ratio, albumin were collected from preoperative day and postoperative days (POD) 0-14.

Official Title
-----------------
The Prognostic Value of Inflammatory Markers for Postoperative Complications in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Conditions
-----------------
Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between September 2014 and April 2017, all patients who underwent cytoreductive surgery and HIPEC for peritoneal carcinomatosis Exclusion Criteria: A Patient treated the dexmedetomidine.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1/NC<br>noninfective complication | |
| 2/IC<br>infective complication | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| inflammatory markers | Retrospectively, C-reactive protein (CRP), neutrophil-to-lymphocyte ratio, white blood cell count, platelet count, mean platelet volume, platelet-to-lymphocyte ratio, albumin were collected using electronic medical record from preoperative day and postoperative days (POD) 0-14. | up to 2 weeks |
Measurement of Tracheobronchial Tree Using 3D CT

Study Overview
=================
Brief Summary
-----------------
Anatomical variations of right main bronchus have been discouraged anesthesiologists' use of right-sided double lumen tubes to facilitate one-lung anesthesia. However, there are absolute indications of right-sided DLTs surgically, such as left pneumonectomy or in cases with left main endobronchial lesions. With recent advances of 3-dimensional spiral CT reconstruction technique, the investigators conducted this retrospective study to measure accurate length of right and left main bronchus and the angle between the center of the right main bronchus and right upper lobe orifice in axial image to help choosing and further manufacturing right-sided double-lumen tubes.

Detailed Description
-----------------
All CT images will be reviewed using the image measurement software with a slice thickness of 1 mm. A level of -450 Hounsfield units and a width of 1000 Hounsfield units were used for bronchial window settings. The length of right and left main bronchus will be measured from the tracheal bifurcation to the point of their first branches, respectively, in both 2D- and 3D-CT images. The anteroposterior angulation of right upper lobar bronchus will be measured from the axial 2D-images by the angle between the horizontal midline of the right main bronchus and the center of the RUL orifice which indicates the origin of the RUL bronchus in which the right upper lobar bronchus shows maximal diameter.

Official Title
-----------------
Measurement of Tracheobronchial Tree Using Multiplane CT Reconstructions to Guide Selecting Double-lumen Tubes

Conditions
-----------------
Double Lumen Tube, Computed Tomography

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 3D- thoracic CT scan images obtained between March 1st and October 31th, 2016 Exclusion Criteria: younger than 18 with intraluminal lesions in main bronchus with abnormalities of tracheobronchial tree with history of tracheobronchial injury or surgery diagnosed musculoskeletal deformity.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| right upper lobe orifice | the angle between the center of the right main bronchus and right upper lobe orifice in axial image | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of right and left main bronchus | accurate length of both main stem bronchi measured by 3D CT | through study completion, an average of 1 year |
Chest Wall Repair of Rib Fractures After Trauma

Study Overview
=================
Brief Summary
-----------------
This is a prospective, observational trial of 50 patients who have multiple, severe rib fractures following trauma. The investigators will follow their hospital stay for outcomes (infections, length of stay and medical care) as well as their early post-hospital course.

Detailed Description
-----------------
Hypothesis: Rib fracture repair utilizing open reduction and internal fixation with commercially available rib plating systems improves outcomes (i.e., infectious complications), decreases hospital stay and mortality. Study Design: This is a prospective, observational study of 50 patients who, due to their injury pattern, are operative candidates for open reduction and internal fixation with commercial available rib plating systems for one of the following indications: Flail chest with/without failure to wean from the ventilator Significantly displaced rib fractures with/without lung impalement Symptomatic multiple rib fractures - Failure of pain control Outcome measures to be evaluated include: Hospital Mortality Ventilator free days Need for tracheotomy Infectious Complications (pneumonia, bacteremia, UTI, empyema) Hospital & ICU Days Disposition following discharge

Official Title
-----------------
Chest Wall Stabilization for Traumatic Chest Wall Injuries: An Observational Study

Conditions
-----------------
Rib Fractures

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must be at least >18 years of age Subjects must have one of the following clinical indications: >3 rib flail segments with paradoxical chest wall movement Non-repair of defect may result in pulmonary hernia Minimal associated injuries Severely displaced fractures are significantly impeding lung expansion. Failure of narcotics or epidural pain catheter to control pain Exclusion Criteria: Significant pulmonary contusion Significant brain injury (AIS 4 and/or ICP monitoring) Severe associated injuries which, in the opinion of the surgeon will preclude operative chest wall stabilization Subjects not expected to survive the 90-day follow-up period Known pregnancy Prisoners

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| traumatic rib fractures<br> | Other: No intervention<br>* No intervention; observation only<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain scales |  | daily | 
| ventilator requirement |  | daily | 
| hospital days |  | discharge |
The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry

Study Overview
=================
Brief Summary
-----------------
The ongoing LAPCOR (Laboratory AntiPlatelet efficacy and Clinical Outcome Registry) registry was initiated in 2008 at a tertiary care cardiac center, and consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.Patients were included in the registry after having signed an informed consent for participation. No exclusion criterion has been applied for the registry participation. Efficacy of P2Y12 receptor antagonists has been measured by quantitative flow cytometric analysis of vasodilator-stimulated phosphoprotein (VASP) phosphorylation according to the manufacturer protocol (Platelet VASP; Diagnostica Stago, Biocytex, Asnières, France) on a FACScan flow cytometer (Becton Dickinson). Occurrence of major adverse cardiac events at 30 days, 6-months and one year follow up has been investigated.

Official Title
-----------------
The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry

Conditions
-----------------
Platelet Aggregation Onhibitors

Intervention / Treatment
-----------------
* Drug: antiplatelet drugs - P2Y12 antagonists


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients after stent PCI treated with P2Y12 antagonist Written informed consent Exclusion Criteria: - None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| stent-PCI patients<br>Consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis. | Drug: antiplatelet drugs - P2Y12 antagonists<br> <br> * Other names: clopidogrel, prasugrel, ticagrelor;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| laboratory efficacy of antiplatelet drugs measured as residual platelet reactivity, incidence of major adverse cardiovascular events and bleeding complications |  | During the 12 months after implantation of an intracoronary stent | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
antiplatelets, percutanous coronary intervention, acute coronary syndromes, laboratory efficacy
Proprioception and Eye-head Coordination for the Cervical Spine

Study Overview
=================
Brief Summary
-----------------
Specific aims of this project were as follows: To investigate the eye-head coordination of patients with cervical spine degeneration. To investigate the relationship of these impairment measurements (range of motion, muscle power, proprioception, sensory threshold, eye-head coordination) and functional outcome (neck disability index, quality of life evaluation). To develop a computer assistant device and software for the proprioceptive training and eye-head coordination. To provide a treatment and prevention program emphasized on proprioception treatment and coordination for employee with neck-shoulder complaints.

Official Title
-----------------
Proprioception and Eye-head Coordination for the Cervical Spine

Conditions
-----------------
Spinal Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Group one: participants without degenerated disease in cervical spine Group two: participants with degenerated disease in cervical spine Exclusion Criteria: Grade III, IV degenerated cervical spine

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
eye-head coordination, proprioception, cervical spine with degenerative disease, degenerated cervical spine
With Continuity of Covid-19 Pandemic, Have Our Anethetic Choices for Caesrean Section Changed ?

Study Overview
=================
Brief Summary
-----------------
This retrospective analytic study will be petformed to investigate if there was a change in the choice of anaethetic technique for caesarean sections with continuation of the COVID-19 pandemic .

Detailed Description
-----------------
The number of regional and general anethesia techniques used with detailed number ofspinals epidurals as well as combined spinal epidurals that were provided .

Official Title
-----------------
Retrospective Analytic Study Will be Performed to Investigate if There Was a Change in the Choice of Anethetic Technique for Casrean Section With Continuation of Covid-19 Pandemic

Conditions
-----------------
COVID-19 Pandemic

Intervention / Treatment
-----------------
* Other: On the period of covid 19


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: pregnant women suspected or infected with covid-19 women undergo cesarean section . Exclusion criteria: normal delivery abortion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Spinal anethesia<br>group number one which recive spinal anethesia in cesarean section in 2020 and 2021 | Other: On the period of covid 19<br>* In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section<br>|
| General anesthesia<br>Group number 2 which recive general anathesia in cesarean section in 2020 snd 2021 | Other: On the period of covid 19<br>* In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type of anethesia | Number of general and regional anethesia used in pregnant women | 2020,2021 | 
| Out come of mother | Number of cases whose admitted to icu post operative | 2 years 2020,2021 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Income of mother | Numbers of patient whose suspected or infected with covid-19 | 2020,2021 |
SYR-472 Open-label Study

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: SYR-472


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -1. The participant is judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator. 2. The participant can sign and date a written, informed consent form prior to the initiation of any study procedures. Exclusion Criteria: -1. The participant has concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease . 2. The participant is assessed to be ineligible for the study by the investigator or subinvestigator.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SYR-472 100mg<br>SYR-472 100mg | Drug: SYR-472<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood Glucose | Blood Glucose | 7 days |
An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

Study Overview
=================
Brief Summary
-----------------
28-Day double-blinded efficacy and safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.

Official Title
-----------------
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis (HOPE-1 Study: Hydration for Optimal Pulmonary Effectiveness)

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Drug: Placebo Inhalation Solution
* Drug: SPX-101


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of cystic fibrosis ppFEV1 (percent predicted FEV1) between 50.0% and 80.0% Stable CF Lung Disease Males and non-pregnant, non-lactating females Exclusion Criteria: Significant unstable co-morbidities within 28 days of screening Has received an investigational drug within 28 days of screening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Placebo Inhalation solution twice daily for 28 days. | Drug: Placebo Inhalation Solution<br>* Normal Saline Inhalation Solution<br>|
| Experimental: SPX-101 Low Dose<br>Inhalation solution twice daily for 28 days. | Drug: SPX-101<br>* SPX-101 Inhalation Solution<br>|
| Experimental: SPX-101 High Dose<br>Inhalation solution twice daily for 28 days. | Drug: SPX-101<br>* SPX-101 Inhalation Solution<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Percent Predicted FEV1 |  | Baseline and Day 28 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Adverse Events |  | Day 1 through Day 28 | 
| Change From Baseline Through Day 28 in Clinical Laboratory Tests | Chemistry, Hematology, Urinalysis | Day 1 through Day 28 |
the Prognosis of Fetoscopy Treatment of Twin Transfusion Syndrome

Study Overview
=================
Brief Summary
-----------------
Fetal medicine in China is still a new, young discipline, and the development is very rapid. After nearly 10 years of development, the clinical diagnosis and treatment guidelines of some complicated twin diseases has been established. Among them, twin-to-twin-transfusion syndrome (TTTS) is serious disease in twin pregnancy, and the factors affecting prognosis after fetoscopic laser surgery are part of the study. Through this study, the investigators expect to achieve better prediction indicators of the prognosis of TTTS.

Detailed Description
-----------------
A better guideline for twin-to-twin-transfusion syndrome are anticipated to be established in China. Fetoscopic laser surgery is applied to treat TTTS. After surgery, better prediction indicators of the prognosis of TTTS are needed.

Official Title
-----------------
the Prognosis of Fetoscopy Treatment of Twin Transfusion Syndrome in Shengjing Hospital

Conditions
-----------------
Twin Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: TTTS after fetoscopic laser surgery. Exclusion Criteria: Pregnant women who refuse to take part in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight in kilogram of neonate | Including twin pregnancy of TTTS after fetoscopic laser surgery measured by nurses | At birth of neonate | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurodevelopment at early childhood | Including adaptive, gross motor, fine motor, language, and social function; assessed using Gesell Developmental Schedules. | At age of 1 year old | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TTTS